PUBLISHER: The Business Research Company | PRODUCT CODE: 1387976
PUBLISHER: The Business Research Company | PRODUCT CODE: 1387976
“Prenatal Testing & Newborn Screening Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on prenatal testing & newborn screening market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for prenatal testing & newborn screening? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The prenatal testing & newborn screening market global report ” from The Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Prenatal testing and newborn screening examinations serve as diagnostic procedures designed to identify potential birth defects in newborns, contributing to the assessment of the baby's overall health.
The primary diagnostic categories within prenatal testing and newborn screening encompass non-invasive and invasive methods. Invasive diagnostic testing involves procedures that penetrate the skin or body, including techniques such as blood testing, biopsies, and colonoscopies. These diagnostic methods leverage various technologies, including screening and diagnostic technology, and are applied across a range of sectors, including hospitals and diagnostic centers.
The prenatal testing & newborn screening market research report is one of a series of new reports from The Business Research Company that provides prenatal testing & newborn screening market statistics, including prenatal testing & newborn screening industry global market size, regional shares, competitors with prenatal testing & newborn screening market share, detailed prenatal testing & newborn screening market segments, market trends and opportunities, and any further data you may need to thrive in the prenatal testing and newborn screening tests industry. This prenatal testing and newborn screening tests market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The prenatal testing & newborn screening market size has grown rapidly in recent years. It will grow from $5.52 billion in 2023 to $6.2 billion in 2024 at a compound annual growth rate (CAGR) of 12.4%. The growth observed during the historical period can be attributed to various factors, including advancements in genetic testing, a rising maternal age, increased awareness and education regarding prenatal and newborn health, as well as changes in healthcare policies and regulations.
The prenatal testing & newborn screening market size is expected to see rapid growth in the next few years. It will grow to $9.76 billion in 2028 at a compound annual growth rate (CAGR) of 12.0%. The projected growth in the forecast period can be attributed to factors such as the increasing adoption of genetic counseling, ongoing technological advancements, the expansion of point-of-care testing, and the rise of telehealth and remote monitoring. Prominent trends in this forecast period encompass the utilization of non-invasive prenatal testing (NIPT), preimplantation genetic testing (PGT), telemedicine consultations for prenatal and newborn health, maternal blood testing, as well as the focus on screening for hemoglobinopathies and sickle cell disease.
The growth of the prenatal testing and newborn screening market is significantly driven by the high prevalence of genetic diseases in infants. The World Health Organization identifies genetic diseases such as Thalassemia, Sickle Cell Anemia, Hemophilia, Cystic Fibrosis, Tay Sachs disease, Fragile X Syndrome, and Huntington's disease. Among these, Sickle Cell Anemia, which predominantly affects individuals with African, American, Cuban, Central American, Saudi Arabian, and Indian ancestry, is particularly widespread. For instance, in November 2021, the National Center for Biotechnology Information reported that genetic diseases were diagnosed in 9.4% of pediatric patients, with 44.7% of these cases occurring in critically ill newborns. This heightened prevalence of genetic diseases in infants has driven the demand for prenatal testing and newborn screening.
The prenatal testing and newborn screening market is poised for growth due to an increase in birth rates. Prenatal testing assesses the health of fetuses before birth, while newborn screening detects specific medical conditions shortly after birth, enabling early intervention when necessary. For example, in May 2022, the Centers for Disease Control and Prevention reported a 1% increase in births in 2021, totaling 3,659,289 births. The general fertility rate also rose to 56.6 births per 1,000 women aged 15-44, reflecting a 1% increase from 2020. Therefore, the rising birth rate is a key driver of the prenatal testing and newborn screening market.
The growth of the prenatal testing and newborn screening market may face challenges in developing countries with relatively limited healthcare access compared to developed nations. For instance, in May 2021, the American Hospital Association warned of a looming shortage of approximately 124,000 physicians in the United States by 2033, along with a need to recruit at least 200,000 nurses annually to meet growing demand and replace retiring nurses. In many developing nations, inadequate access to healthcare services, a shortage of hospitals and healthcare professionals, and low disposable income levels are factors that hinder market growth. This limited access to healthcare services adversely impacts the expansion of the prenatal testing and newborn screening market in such regions.
The adoption of machine learning and artificial intelligence is gradually gaining traction in the prenatal testing and newborn screening market. Artificial intelligence (AI) and machine learning aid companies in the market in conducting comprehensive data analysis, providing insights about various diseases, and delivering more precise evaluations of tissue samples. For example, in September 2021, Sema4 introduced Sema4 Elements, a suite of genetic solutions that leverage artificial intelligence and information-driven digital tools for both patients and healthcare providers. These tools aim to support comprehensive healthcare management for expectant mothers and infants within the realms of reproductive and generational health.
Major companies operating in the prenatal testing and newborn screening market are actively forming strategic partnerships. These collaborations aim to bolster research, innovation, and market access, thereby enhancing the quality of healthcare services for expectant mothers and newborns. For instance, in December 2021, OZ Systems, a health technology company, partnered with PerkinElmer Inc., a provider of genetic testing, newborn and prenatal screening, to improve newborn testing through the development of cloud-based information management systems. This strategic partnership seeks to proactively identify and diagnose health conditions in newborns to prevent disabilities and save lives.
In January 2022, Exact Sciences Corp., a molecular diagnostics company, completed the acquisition of Prevention Genetics for $190 million. This acquisition enhances Exact Sciences' advanced cancer diagnostics portfolio and allows the company to enter the hereditary cancer testing (HCT) market. Prevention Genetics, a company specializing in clinical DNA (genetic) tests for prenatal testing and newborn screening, complements Exact Sciences' capabilities and expands its market presence.
Major companies operating in the prenatal testing & newborn screening market include PerkinElmer Inc., Laboratory Corporation of America Holdings (LabCorp), Natera Inc., Invitae Corporation, Centogene AG, Cradle Genomics Inc., Roche Diagnostics International AG, Quest Diagnostics Incorporated, Baebies Inc., Progenity Inc., Ravgen Inc., Strand Life Sciences Pvt. Ltd., Eurofins Scientific, Illumina Inc., Agilent Technologies Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories Inc., General Electric Company, Siemens Healthineers AG, BGI Group, QIAGEN N.V., Veracyte Inc., NIPD Genetics, Novacyt UK, Ariosa Diagnostics Inc., Verinata Health Inc., Counsyl a Myriad Company, GenPath Diagnostics, Sonic Healthcare Limited, Cepheid a Danaher Company, Guardant Health Inc., Genetron Health (Beijing) Co. Ltd.
North America was the largest region in the prenatal testing & newborn screening market in 2023. Western Europe was the second largest region in the prenatal testing and newborn screening market. The regions covered in the prenatal testing & newborn screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the prenatal testing & newborn screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada
The prenatal testing & newborn screening market includes revenues earned by entities by providing blood test services, hearing test services, CCHD screening tests, and non-invasive tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.